




RealRate

PHARMACEUTICAL 2021

Chinook Therapeutics INC
Rank 115 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Chinook Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Chinook Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 93% points. The greatest weakness of Chinook Therapeutics INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 334%, being 78% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	254,081
Cost of Goods Sold	0
Intangible Assets	50,137
Liabilities, Current	22,809
Liabilities, Non-Current	39,614
Other Assets	124,784
Other Compr. Net Income	18
Other Expenses	27,640
Other Liabilities	31,957
Other Net Income	313
Other Revenues	827
Property and Equipment	0
Research and Development	36,051
Selling, General and Administrative Expense	19,071

Output Variable	Value in 1000 USD
Assets	429,002
Liabilities	94,380
Expenses	82,762
Revenues	827
Stockholders Equity	334,622
Net Income	-81,622
Comprehensive Net Income	-81,613
BaseVar	303,651
ECR before LimitedLiability	248%
Economic Capital Ratio	334%